Editas Medicine (EDIT) Stock
Biotech company developing gene editing therapies for diseases. Here's the price, business snapshot, and what's worth knowing about Editas Medicine in August 2026.
Editas Medicine (EDIT) is a clinical-stage biotechnology company focused on developing gene-editing therapies using CRISPR-based technologies. The firm aims to correct disease-causing genetic variants for rare and common disorders, with a pipeline that includes in‑vivo and ex‑vivo programmes. As of the given market data, Editas is a small-cap company (market cap ~ $349m), which often means higher share-price volatility and greater sensitivity to clinical and funding news. Key points for investors: clinical-trial results, regulatory decisions, partnership announcements and financing plans can materially affect the stock. There is the potential for significant upside if trials succeed, but also a meaningful risk of setbacks, delays and dilution. This summary is for educational purposes only and not personal investment advice; always consider your risk tolerance, time horizon and consult a qualified adviser before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Editas Medicine's stock with a target price of $7.26, indicating potential growth.
Financial Health
EDITAS Medicine has modest revenue and cash flow, but low book value per share indicates some concerns.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring EDIT
LNP Patent Holders Shape Drug Delivery Value 2025
The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
Published: 4 March 2026
Explore BasketInvestment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: 18 September 2025
Explore BasketBeyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: 5 August 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: 30 July 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: 21 July 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: 11 July 2025
Explore BasketHope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Published: 18 June 2025
Explore BasketSynthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage Pipeline
Several programmes are in or approaching clinical evaluation, so trial readouts can be major catalysts — though outcomes can also disappoint.
Catalysts and Risks
Near-term catalysts include study results and partnerships; balance this with regulatory uncertainty and potential dilution from fundraising.
Technology Potential
CRISPR-based approaches aim to address genetic disease at the source, offering transformative potential, but commercial and safety hurdles remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
